Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: J Allergy Clin Immunol. 2020 Jan 13;145(6):1664–1672.e10. doi: 10.1016/j.jaci.2019.12.908

Table 2.

Characterization of ADA2 mutations

Protein cDNA n Phenotype Type Domain ADA2 activity (%WT) Published phenotype [ref#]
G47W c.139G>T 1 BMF missense Dimerization 0.3 ± 0.5 Vasculitis * 25
R49Afs*13 c.137dupT 4 PRCA, BMF frameshift Dimerization UD Hemolytic anemia 8
F178S c.533T>C 2 BMF missense Catalytic 0.8 ± 0.6 PRCA 8
F212del c.634_636delTTC 1 BMF deletion Catalytic 0.8 ± 1.2 -
G321E c.962G>A 1 PRCA missense Catalytic 1.8 ± 1.0 BMF 18
G358R c.1072G>A 4 BMF missense Catalytic 1.7 ± 0.6 PRCA 6
K449Nfs*2 c.1346_1347insTT 1 BMF frameshift Catalytic UD -
K466Tfs*2 c.1397_1403AGGCTGAdel 1 BMF frameshift Catalytic UD PRCA 10
V458D c.1373T>A 1 BMF missense Catalytic 2.4 ± 0.4 BMF 13 Vasculitis * 26

Abbreviations: UD, undetectable.

*

This mutation was previously described in a patient with compound heterozygous mutations.